Roche has obtained U.S. government green lights allowing its point-of-care testing system to be used to screen for multiple sexually transmitted infections from a single sample. | The company’s cobas ...
Leveraging gold-standard PCR technology, the cobas liat system claims to deliver outcomes in under 20 minutes.
Hoffmann has been vice-chair of Roche since 2006 and a board director since 1996. Among many other roles, he is a trustee of ...
The cobas liat test aims to improve patient outcomes by offering rapid, accurate results in decentralized and community-based ...
Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his team of dealmakers can juggle them.
Firefighters in Worcester, Massachusetts had to deal with extreme heat and cold Wednesday morning as temperatures dropped to ...
Roche plans to release the system in the US to run tests including vitamin D and steroid assays under CLIA before it possibly receives US Food and Drug Administration clearance.
The rise of GLP-1s have made treating obesity one of the largest market opportunities in history. It also has reinforced a ...
More than 1 million curable sexually transmitted infections (STIs) are acquired every day worldwide in people 15–49 years old, most of which are asymptomatic.1 FDA CLIA-waived tests broaden access to ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received 510(k) clearance from the United States Food and Drug ...
J.P. Morgan analyst Richard Vosser maintained a Sell rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback